KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Encompass Health (EHC) Minority Interest (2016 - 2025)

Encompass Health (EHC) has disclosed Minority Interest for 17 consecutive years, with $779.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest rose 1279.29% year-over-year to $779.3 million, compared with a TTM value of $779.3 million through Dec 2025, up 1279.29%, and an annual FY2025 reading of $779.3 million, up 1279.29% over the prior year.
  • Minority Interest was $779.3 million for Q4 2025 at Encompass Health, up from $56.5 million in the prior quarter.
  • Across five years, Minority Interest topped out at $779.3 million in Q4 2025 and bottomed at $31.7 million in Q1 2021.
  • Average Minority Interest over 5 years is $182.0 million, with a median of $43.2 million recorded in 2022.
  • Peak annual rise in Minority Interest hit 1416.92% in 2022, while the deepest fall reached 89.54% in 2022.
  • Year by year, Minority Interest stood at $42.2 million in 2021, then dropped by 15.64% to $35.6 million in 2022, then rose by 17.98% to $42.0 million in 2023, then surged by 34.52% to $56.5 million in 2024, then surged by 1279.29% to $779.3 million in 2025.
  • Business Quant data shows Minority Interest for EHC at $779.3 million in Q4 2025, $56.5 million in Q4 2024, and $48.6 million in Q2 2024.